Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor
Philipp B. Staber, Wojciech Jurczak, Richard Greil, Vladan Vučinić, Jan Moritz Middeke, Marco Montillo, Talha Munir, Peter Neumeister, Johannes Schetelig, Stephan Stilgenbauer, Frank Striebel, Maren Dirnberger‐Hertweck, Johannes Weirather, Wolfram Brugger, P. B. Kelemen, Clemens‐Martin Wendtner, Jennifer A. Woyach
Abstract
= 13, median time on study, 15.6 months). The most common treatment-emergent adverse event (TEAE) in cohort A was anemia (63.6%) and in cohort B was infusion-related reaction (53.8%). The most common severe TEAE was neutropenia (cohort A: 45.5%; cohort B: 46.2%). The best overall response rate was 90.9% (cohort A) and 76.9% (cohort B). Undetectable minimal residual disease in peripheral blood was achieved in 2/8 patients (cohort A) and 6/7 patients (cohort B). Overall, these results suggest that anti-CD19 antibody-based combinations may be important in the treatment of patients with CLL.